Treatment strategies to improve and sustain remission in major depressive disorder

Madhukar H. Trivedi, Ella J. Daly

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Major depressive disorder (MDD) is an often chronic, recurrent illness affecting large numbers of the general population. In recent years, the goal of treatment for MDD has moved from mere symptomatic response to that of full remission (ie, minimal/no residual symptoms). The recent Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial showed that even with systematic measurement-based treatment, approximately one third of patients reach full remission after one treatment trial, with only two thirds reaching remission after four treatment trials. Treatment-resistant depression (TRD) is therefore a common problem in the treatment of MDD, with 60% to 70% of all patients meeting the criteria for TRD. Given the huge burden of major depressive illness, the low rate of full recovery remains suboptimal. The following article reports on some current treatment strategies available to improve rates of, and to sustain, remission in MDD.

Original languageEnglish (US)
Pages (from-to)377-384
Number of pages8
JournalDialogues in Clinical Neuroscience
Volume10
Issue number4
StatePublished - 2008

Fingerprint

Major Depressive Disorder
Treatment-Resistant Depressive Disorder
Therapeutics
Chronic Disease
Depression
Population

Keywords

  • Function
  • Remission
  • Treatment-resistant depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Treatment strategies to improve and sustain remission in major depressive disorder. / Trivedi, Madhukar H.; Daly, Ella J.

In: Dialogues in Clinical Neuroscience, Vol. 10, No. 4, 2008, p. 377-384.

Research output: Contribution to journalArticle

@article{c556ef3dae5443b1862a18fd38eb1873,
title = "Treatment strategies to improve and sustain remission in major depressive disorder",
abstract = "Major depressive disorder (MDD) is an often chronic, recurrent illness affecting large numbers of the general population. In recent years, the goal of treatment for MDD has moved from mere symptomatic response to that of full remission (ie, minimal/no residual symptoms). The recent Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial showed that even with systematic measurement-based treatment, approximately one third of patients reach full remission after one treatment trial, with only two thirds reaching remission after four treatment trials. Treatment-resistant depression (TRD) is therefore a common problem in the treatment of MDD, with 60{\%} to 70{\%} of all patients meeting the criteria for TRD. Given the huge burden of major depressive illness, the low rate of full recovery remains suboptimal. The following article reports on some current treatment strategies available to improve rates of, and to sustain, remission in MDD.",
keywords = "Function, Remission, Treatment-resistant depression",
author = "Trivedi, {Madhukar H.} and Daly, {Ella J.}",
year = "2008",
language = "English (US)",
volume = "10",
pages = "377--384",
journal = "Dialogues in Clinical Neuroscience",
issn = "1294-8322",
publisher = "Servier International",
number = "4",

}

TY - JOUR

T1 - Treatment strategies to improve and sustain remission in major depressive disorder

AU - Trivedi, Madhukar H.

AU - Daly, Ella J.

PY - 2008

Y1 - 2008

N2 - Major depressive disorder (MDD) is an often chronic, recurrent illness affecting large numbers of the general population. In recent years, the goal of treatment for MDD has moved from mere symptomatic response to that of full remission (ie, minimal/no residual symptoms). The recent Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial showed that even with systematic measurement-based treatment, approximately one third of patients reach full remission after one treatment trial, with only two thirds reaching remission after four treatment trials. Treatment-resistant depression (TRD) is therefore a common problem in the treatment of MDD, with 60% to 70% of all patients meeting the criteria for TRD. Given the huge burden of major depressive illness, the low rate of full recovery remains suboptimal. The following article reports on some current treatment strategies available to improve rates of, and to sustain, remission in MDD.

AB - Major depressive disorder (MDD) is an often chronic, recurrent illness affecting large numbers of the general population. In recent years, the goal of treatment for MDD has moved from mere symptomatic response to that of full remission (ie, minimal/no residual symptoms). The recent Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial showed that even with systematic measurement-based treatment, approximately one third of patients reach full remission after one treatment trial, with only two thirds reaching remission after four treatment trials. Treatment-resistant depression (TRD) is therefore a common problem in the treatment of MDD, with 60% to 70% of all patients meeting the criteria for TRD. Given the huge burden of major depressive illness, the low rate of full recovery remains suboptimal. The following article reports on some current treatment strategies available to improve rates of, and to sustain, remission in MDD.

KW - Function

KW - Remission

KW - Treatment-resistant depression

UR - http://www.scopus.com/inward/record.url?scp=59149086690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149086690&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 377

EP - 384

JO - Dialogues in Clinical Neuroscience

JF - Dialogues in Clinical Neuroscience

SN - 1294-8322

IS - 4

ER -